- Supported exchanges /
- NASDAQ /
- EIGRQ.NASDAQ
Eiger BioPharmaceuticals Inc (EIGRQ NASDAQ) stock market data APIs
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development of therapies for hepatitis delta virus (HDV) and other serious diseases. The company offers Zokinvy for the treatment of Hutchinson-Gilford progeria syndrome and Processing-Deficient Progeroid Laminopathies. Its product candidates include Lonafarnib, an orally available, farnesylation inhibitor, which has completed Phase 3 clinical trials for HDV infection; Peginterferon Lambda (lambda), which is in clinical development for HDV; lambda, that is in phase II and III investigator studies of mild and moderate COVID-19; and Avexitide, which is in Phase II for the treatment of congenital hyperinsulinism and post-bariatric hypoglycemia. The company is headquartered in Palo Alto, California. On April 1, 2024, Eiger BioPharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Northern District of Texas.
Eiger BioPharmaceuticals Inc Financial Data Overview
| 8.5 | |
| 8.5 | |
| - | |
| 8.5 | |
| 8.5 | |
| 1.1-16 | |
| 11 846 K | |
| 1 481 K | |
| 15 773 K | |
| 2.776 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Eiger BioPharmaceuticals Inc Fundamental Data is available in our Financial Data APIs
- Net Revenue 15 773 K
- EBITDA -71 511 000
- Earnings Per Share -11.74
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Eiger BioPharmaceuticals Inc Earnings via APIs
- Latest Release 2024-10-02
- EPS/Forecast NaN
Get Eiger BioPharmaceuticals Inc End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
